Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the Chairman's Address provided by Mr Neville Gardiner and the Investor Presentation provided by Dr Richard Lipscombe to shareholders.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price in the United States for the PromarkerD predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to provide an opportunity for shareholders and investors to view a virtual presentation by Managing Director Dr Richard Lipscombe.
Proteomics International Laboratories Ltd (ASX:PIQ) announces that its cash reserves have been further strengthened by the receipt of $1.85 million in research and development tax incentive for the 2022-23 financial year.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors.
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2023 and subsequent to the period end.
Apiam Animal Health Limited (ASX:AHX) today announced an update on the Company's performance for the quarter ended 30 September 2023 (Q1 FY24).
